



OMOP 4 SWEDEN!

EVIDENCE GENERATION FOR BETTER HEALTHCARE



Our Event Sponsors



The OMOP 4 Sweden Consortium



The OHDSI Sweden Symposium 2025

Agenda

- 09:00-09:15: Introduction & Opening messages
- 09:15-10:30: The OMOP Common Data Model & OHDSI
- 10:30-11:15: An international perspective
- 11:15-12:00: What can Sweden leverage and learn from other nations working with OMOP?

12:00-13:00: Lunch break



- 13:00-13:30: Sweden's early adopters
- 13:30-15:00: International case studies

15:00-15:30: Fika break

- 15:30-16:15: The Swedish Health Data Ecosystem
- 16:15-17:00: OMOP in the international health informatics standardization landscape
- 17:00-17:15: Wrap-up with final words

17:15-18:00: After event networking and conversations





GAPMINDER

*”With the right type of glasses you can see **the real world.***

*...and then **turn it into value.**”*



”Let’s create a movement!”







» **Sofie Gustafsson**,
Global Director Real World Evidence
Partnerships & Innovation
Pfizer



» **Kristian Bolin**
Professor in Health Economics
Gothenburg University



» **Andreas Hager**
Innovation Lawyer Digitalization
Karolinska University Hospital

Patient Advocate
Upstream Dream



» **Martin Persson**
Patient Representative
Board Member
Network against Cancer

09:15 – 09:45

The OMOP Common Data Model & The OHDSI Community

- The Journey of OHDSI: Where have we been and where can we go together?

» Patrick Ryan, The Janssen Pharmaceutical Companies of Johnson & Johnson, Columbia University, OHDSI International



09:45 – 10:30

The OMOP Common Data Model & The OHDSI Community

- What is OMOP and OHDSI? User groups, use-cases, tools and methods?

- » Renske Los, Erasmus MC, OHDSI Europe, OHDSI NL
- » Jordan Kane, Stiftelsen Chalmers Industriteknik



10:30 – 11:15

An international perspective of OMOP: Experiences, assets and solutions up for grabs for Sweden

The European Health Data & Evidence Network (EHDEN) Project & Foundation

- » Carlos Díaz, EHDEN Foundation, CEO Synapse Research Management Partners

Harnessing Unstructured Data and Hospital Interoperability - The potential of next-generation platforms in transforming patient recruitment

- » Mats Sundgren, i-HD, The European Institute for Innovation Through Health Data, IOMED

The Data Analysis & Real World Interrogation Network (DARWIN-EU)

- » Talita Duarte-Salles, Epidemiologist, Erasmus MC,
DARWIN-EU



10:15 – 12:00

What can Sweden leverage and learn from other nations working with OMOP?

OHDSI Europe and OHDSI Netherlands

- » Renske Los, Erasmus MC

OHDSI Finland

- » Eric Fey, Helsinki University Hospital, Helsinki University

OHDSI UK

- » Alex Knight, Health Data Research UK

OHDSI Belgium

- » Ilse Vermeulen, University of Hasselt, National Node Manager of OHDSI Belgium

OHDSI Norway

- » Espen Enerly, Norwegian Institute of Public Health, Cancer Registry of Norway



12:00 – 13:00

Well Deserved Lunch Time!!!

Our Event Sponsors



passion2improve



OMOP 4 SWEDEN!
EVIDENCE GENERATION FOR BETTER HEALTHCARE

OHDSI
OBSERVATIONAL HEALTH DATA SCIENCES AND INFORMATICS

13:00-13:30

**How does OMOP and OHDSI fit into the Swedish ecosystem of life science and healthcare?
The voices, experiences and recommendations from Sweden's early OMOP adopters.**

- » Rickard Ljung, The Swedish Medical Products Agency (DARWIN-EU Sweden) (repr. Prof. Fredrik Nyberg, Institute of Medicine, University of Gothenburg)
- » Jonas Wastesson, Karolinska Institutet, Dep. Medical Epidemiology and Biostatistics
- » Niklas Norén, Uppsala Monitoring Center



13:30-15:00

Case studies

How RWE can support pharmacovigilance signal management, and OMOP's role in removing barriers

» Niklas Norén, Uppsala Monitoring Center

Global evidence generation with OMOP-harmonized clinical data: case lung cancer

» Kimmo Porkka, University of Helsinki

Development of HEARTwise Machine Learning framework to predict patient deterioration using existing OMOP CDM NEWS variables.

» Lars Halvorsen, edenceHealth
(representing Jan Yperman Hospital & Antwerp University Hospital)

National infrastructure for secondary use of health data. Experiences from England.

» Jake Marshall, Imperial College London

Value from Nordic Health Data (VALO): A Hands-On Case Study of a pan-European Cancer Research Project Using OMOP

» Åslaug Helland, University of Oslo, Oslo University Hospital

A Data Scientist's perspective on the lessons learned

» Iiro Toppila, Medaffcon



15:00-15:30

It's time for fika!!!

Our Event Sponsors



passion2improve



OMOP 4 SWEDEN!
EVIDENCE GENERATION FOR BETTER HEALTHCARE

OHDSI
OBSERVATIONAL HEALTH DATA SCIENCES AND INFORMATICS

15:30-16:15

The Swedish Health Data Ecosystem Panel conversation

What could more access to, and use of harmonized health data mean for Sweden, its national life science strategy and our strategic initiatives?

- » Michel Silvestri, Swedish eHealth Agency
- » Päivi Östling, Karolinska Institutet
- » Sofie Gustafsson, Pfizer
- » Amy Leval, Johnson & Johnson
- » Katrine Riklund, Umeå Universitet & EUCAIM
- » Sebastiaan Meijer, KTH & Health Data Sweden
- » Carl Jarnling, IQVIA Nordics



16:15-17:00

OMOP in the international health informatics standardization landscape

Panel conversation

Moderator: Sabine Koch, Introduction and panel moderator, Karolinska Institutet

Is OMOP another important piece in the jigsaw-puzzle of international health data standards?

- » Daniel Karlsson, Swedish eHealth Agency
- » Mikael Nyström, OpenEHR Sweden and Cambio
- » Niklas Eklöv, National Board of Health and Welfare (Snomed-CT)
- » Vadim Peretokin, HL7 Sweden (FHIR)



17:00 – 17:15

Let's wrap this up!



OMOP in Sweden


Can we ‘Cross the chasm’ with OMOP CDM in Sweden?



Early adopters of OMOP in Sweden

1. The EHDEN initiative (AstraZeneca, UMC)

- WHO’s Uppsala Monitoring Center: EHDEN, Pharmacovigilance evidence-a-thon
- Gothenburg University: SCIFI-PEARL Swedish Covid-19 Investigation
- KI MEB: Institutionen för medicinsk epidemiologi och biostatistik
- KI & Region Sthlm: Stockholm CREATinine Measurements Project: Chronic kidney disease care
- SWIBREG, Region Östergötland: Swedish Inflammatory Bowel Disease Registry



2. DARWIN-EU

- Gothenburg University: SCIFI-PEARL Swedish Covid-19 Investigation
- Läkemedelsverket, Pharmacoepidemiology and Analysis Unit

3. PERMANENS: European initiative in the area of self-harm and suicide prevention

- Participant from SWE: KI, Department of Clinical Neuroscience

passion2improve



sfmi



HUS*



GÖTEBORGS UNIVERSITET

abbvie




SWElife




Our mission!

To move more people and organizations from left to right in the funnel



How's the progress?



Försäkringskassan



Inspektionen för vård och omsorg



Skånes universitetssjukhus



Regeringskansliet
Utbildningsdepartementet

Regeringskansliet
Klimat- och näringslivsdepartementet

Regeringskansliet
Finansdepartementet

Socialstyrelsen




Svenska Tvillingregistret

eHälsomyndigheten



De forskande
Läkemedelsföretagen


SwedAD



KAROLINSKA



LÄKEMEDELSVERKET




Uppsala Monitoring
Centre



OMOP4 SWEDEN!

Why should Sweden invest in harmonizing its health data assets using OMOP?




Common use-cases

- 1. Regulatory Science & Pharmacovigilance**
 - Drug safety signal detection
 - Post-authorisation safety studies (PASS)
 - Comparative effectiveness of therapies
- 2. Public Health & Health System Monitoring**
 - Epidemiology of diseases
 - Vaccine effectiveness & safety
 - Infectious disease surveillance
- 3. Clinical Research & Evidence Generation**
 - Cohort discovery & Characterization studies
 - Linking biobanks/genomics/registry/EHR data
 - RWE for clinical trials
- 4. Interoperability & Federated Networks**
 - Cross-institutional research collaboration
 - Large international federated studies
 - Large health data networks
- 5. Health Technology Assessment (HTA) & Policy**
 - Cost-effectiveness inputs for HTA models
 - Treatment pathway analysis
 - Outcome benchmark analysis
- 6. Primary Care & Precision Medicine**
 - Predictive modelling
 - Clinical Decision Support Systems
 - Translational research

Why?

- 1. Improved Healthcare**
- 2. Higher Efficiency & Effectiveness**
- 3. Increased National Competitiveness**



- 1 Research & Innovation Bill**
 - Health, life science and artificial intelligence
- 2 EHDS + National Infrastructure for Health Data**
 - 2026: 550M 2027: 369M 2028: 323M 2029-: 158M
 - Hard & Soft Infrastructure, SPEs, HDAB, Stds.
- 3 AI & Machine Learning**
 - 2026: 479M SEK, 2027–2030: 500M SEK per year
 - AI & Health is part of this investment (LLMs, NLP)
- 4 Precision Medicine**
 - Genomic Medicine Sweden, SciLifeLab
 - Precision Omics Initiative Sweden (PROMISE)
- 5 Disease-specific Strategies & Initiatives**
 - National Cancer Strategy
 - 26 National Program Areas (often diseases)
- 6 Clinical Trials, Research RWE Studies**
 - SweTrial, Kliniskastudier.se
 - Trial Feasibility, Patient Recruitment, ...
- 7 Clinical Innovation & Development**
 - Data-driven Healthcare
 - Bring innovations to the clinic (TEF Health, SIISH)
- 8 Society Resilience**
 - Infection control and health risks monitoring
 - Pharmacovigilance

It's time to act!

- Government Leaders
- National Authorities
- Healthcare Regions
 - Registries
 - Registry Organisations
- Epidemiologists
- Researchers
 - Academia
- Pharma Industry
- HealthTech Providers
 - Educators
- Patient Organisations
 - Financing Bodies



passion2improve



sfmi



HUS*



GÖTEBORGS UNIVERSITET

abbvie



SWElife



Our Event Sponsors



passion2improve

